Legend Biotech Corp is a biotechnology business based in the US. Legend Biotech Corp shares (LEGN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $38.24 – an increase of 11.88% over the previous week. Legend Biotech Corp employs 2,400 staff and has a trailing 12-month revenue of around $520.2 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $38.24 |
|---|---|
| 52-week range | $30.17 - $69.24 |
| 50-day moving average | $35.28 |
| 200-day moving average | $44.27 |
| Wall St. target price | $79.26 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.92 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $34.03 from 2025-03-10
| 1 week (2025-03-06) | -0.44% |
|---|---|
| 1 month (2025-02-13) | -6.49% |
| 3 months (2024-12-13) | -3.10% |
| 6 months (2024-09-13) | -32.36% |
| 1 year (2024-03-12) | -47.75% |
|---|---|
| 2 years (2023-03-10) | -21.63% |
| 3 years (2022-03-11) | 35.97 |
| 5 years (2020-03-09) | N/A |
| Revenue TTM | $520.2 million |
|---|---|
| Gross profit TTM | $-87,721,000 |
| Return on assets TTM | -12.28% |
| Return on equity TTM | -28.35% |
| Profit margin | -66.92% |
| Book value | $6.08 |
| Market Capitalization | $6.3 billion |
TTM: trailing 12 months
We're not expecting Legend Biotech Corp to pay a dividend over the next 12 months.
Over the last 12 months, Legend Biotech Corp's shares have ranged in value from as little as $30.17 up to $69.24. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Legend Biotech Corp's is 0.195. This would suggest that Legend Biotech Corp's shares are less volatile than average (for this exchange).
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.
Spot dogecoin ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
We analyzed a number of bitcoin ETFs to determine which are best to invest in.
Arrived offers a simple way to invest in real estate rental properties.
3 Northwestern Mutual wealth management alternatives to consider.
Investing in mutual funds offers instant diversification. Learn more.
What you need to know about investing in the leading indicator for the overall US stock market.
Here’s what you need to know about how to buy and sell stocks online in this easy to follow, step-by-step guide.